Home » Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
Nile Therapeutics, a company focused on the development of novel
therapeutics for heart failure patients, announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with
acute decompensated heart failure.
Forbes
Forbes
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May